Collplant Average Payables from 2010 to 2024
| CLGN Stock | USD 4.25 0.00 0.00% |
Average Payables | First Reported 2010-12-31 | Previous Quarter 985.4 K | Current Value 550.4 K | Quarterly Volatility 297.6 K |
Check Collplant Biotechnologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Collplant Biotechnologies' main balance sheet or income statement drivers, such as Depreciation And Amortization of 874.1 K, Interest Expense of 9.5 K or Selling General Administrative of 3.8 M, as well as many indicators such as Price To Sales Ratio of 6.31, Dividend Yield of 0.0 or PTB Ratio of 4.81. Collplant financial statements analysis is a perfect complement when working with Collplant Biotechnologies Valuation or Volatility modules.
Collplant | Average Payables |
Latest Collplant Biotechnologies' Average Payables Growth Pattern
Below is the plot of the Average Payables of Collplant Biotechnologies over the last few years. It is the average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers. Collplant Biotechnologies' Average Payables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Collplant Biotechnologies' overall financial position and show how it may be relating to other accounts over time.
| Average Payables | 10 Years Trend |
|
Average Payables |
| Timeline |
Collplant Average Payables Regression Statistics
| Arithmetic Mean | 849,287 | |
| Geometric Mean | 793,752 | |
| Coefficient Of Variation | 35.04 | |
| Mean Deviation | 280,078 | |
| Median | 1,094,850 | |
| Standard Deviation | 297,568 | |
| Sample Variance | 88.5B | |
| Range | 617.5K | |
| R-Value | 0.57 | |
| Mean Square Error | 64.2B | |
| R-Squared | 0.33 | |
| Significance | 0.03 | |
| Slope | 38,037 | |
| Total Sum of Squares | 1.2T |
Collplant Average Payables History
About Collplant Biotechnologies Financial Statements
Collplant Biotechnologies investors utilize fundamental indicators, such as Average Payables, to predict how Collplant Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Average Payables | 985.4 K | 550.4 K |
Pair Trading with Collplant Biotechnologies
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Collplant Biotechnologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Collplant Biotechnologies will appreciate offsetting losses from the drop in the long position's value.Moving together with Collplant Stock
| 0.82 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.81 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against Collplant Stock
| 0.8 | PHVS | Pharvaris BV | PairCorr |
| 0.69 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
| 0.63 | PMVP | Pmv Pharmaceuticals | PairCorr |
| 0.61 | NAMS | NewAmsterdam Pharma | PairCorr |
| 0.61 | PLRX | Pliant Therapeutics | PairCorr |
The ability to find closely correlated positions to Collplant Biotechnologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Collplant Biotechnologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Collplant Biotechnologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Collplant Biotechnologies to buy it.
The correlation of Collplant Biotechnologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Collplant Biotechnologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Collplant Biotechnologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Collplant Biotechnologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Collplant Biotechnologies Correlation against competitors. To learn how to invest in Collplant Stock, please use our How to Invest in Collplant Biotechnologies guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collplant Biotechnologies. If investors know Collplant will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collplant Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.53) | Revenue Per Share 0.06 | Quarterly Revenue Growth (0.98) | Return On Assets (0.34) | Return On Equity (0.62) |
The market value of Collplant Biotechnologies is measured differently than its book value, which is the value of Collplant that is recorded on the company's balance sheet. Investors also form their own opinion of Collplant Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Collplant Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collplant Biotechnologies' market value can be influenced by many factors that don't directly affect Collplant Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Collplant Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Collplant Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collplant Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.